Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles: 2012-2025

Historic Intangibles for Ani Pharmaceuticals (ANIP) over the last 13 years, with Sep 2025 value amounting to $499.8 million.

  • Ani Pharmaceuticals' Intangibles fell 12.29% to $499.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $499.8 million, marking a year-over-year decrease of 12.29%. This contributed to the annual value of $541.8 million for FY2024, which is 159.24% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Intangibles stood at $499.8 million for Q3 2025, which was down 3.94% from $520.3 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Intangibles ranged from a high of $569.8 million in Q3 2024 and a low of $170.1 million during Q3 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Intangibles value was $499.8 million (recorded in 2025), while the average stood at $383.3 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Intangibles surged by 198.28% in 2022, and later crashed by 61.37% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Intangibles (Quarterly) stood at $500.5 million in 2021, then slumped by 49.72% to $251.6 million in 2022, then decreased by 16.94% to $209.0 million in 2023, then skyrocketed by 159.24% to $541.8 million in 2024, then decreased by 12.29% to $499.8 million in 2025.
  • Its last three reported values are $499.8 million in Q3 2025, $520.3 million for Q2 2025, and $538.5 million during Q1 2025.